Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2021 Jul 14;11:14478. doi: 10.1038/s41598-021-91644-y

Exposure–lag response of smoking prevalence on lung cancer incidence using a distributed lag non-linear model

Daniel Robert Smith 1,, Alireza Behzadnia 2, Rabbiaatul Addawiyah Imawana 1, Muzammil Nahaboo Solim 3, Michaela Louise Goodson 1
PMCID: PMC8280159  PMID: 34262067

Abstract

The prevalence of smokers is a major driver of lung cancer incidence in a population, though the “exposure–lag” effects are ill-defined. Here we present a multi-country ecological modelling study using a 30-year smoking prevalence history to quantify the exposure–lag response. To model the temporal dependency between smoking prevalence and lung cancer incidence, we used a distributed lag non-linear model (DLNM), controlling for gender, age group, country, outcome year, and population at risk, and presented the effects as the incidence rate ratio (IRR) and cumulative incidence rate ratio (IRRcum). The exposure–response varied by lag period, whilst the lag–response varied according to the magnitude and direction of changes in smoking prevalence in the population. For the cumulative lag–response, increments above and below the reference level was associated with an increased and decreased IRRcum respectively, with the magnitude of the effect varying across the lag period. Though caution should be exercised in interpretation of the IRR and IRRcum estimates reported herein, we hope our work constitutes a preliminary step towards providing policy makers with meaningful indicators to inform national screening programme developments. To that end, we have implemented our statistical model a shiny app and provide an example of its use.

Subject terms: Oncology, Risk factors

Introduction

Globally, lung cancer accounts for 11.6% and 18.4% of all cancer cases and deaths respectively1. In 2018, lung cancer accounted for 1.79 million deaths globally, with 2.09 million new cases diagnosed. Tobacco use is the primary cause of most lung cancers2,3, and although other methods of tobacco consumption have emerged, smoking remains by far the most common4.

The World Health Organization (WHO) estimates tobacco related mortality will increase from 100 million in the twentieth century to one billion in twenty-first century if current trends in smoking continue3. To circumvent this epidemic, the WHO Framework Convention on Tobacco Control (FCTC), the first ever global health treaty, was initiated in 2003, with the overarching goal of implementing effective policies to reduce tobacco consumption5. In 2013, WHO set the target of a 30% smoking prevalence reduction by 2025 in all 178 countries that signed the FCTC. Projections based on limited publicly available data have shown that less than half of these countries are likely to meet this target2,6. Between 2009 and 2017, smoking prevalence declined by 7.7% (male) and 15.2% (female) globally7. This decline has been the trend for the majority of high-income countries8, though some nations (e.g. Males in Albania; Females in Portugal) have seen substantial increases during this period7. Nevertheless, the impact and burden of lung cancer attributed to smoking prevalence on global healthcare systems is likely to persist for decades8.

The causal link between smoking behaviour and risk of lung cancer is well established912. However, ecological models that have incorporated smoking data have focused on mortality (rather than incidence), and being projection models, are optimised for predictive accuracy as opposed to estimation of the exposure–lag response13. The latter calls for explanatory modelling; this will be invaluable to policy makers for estimating the effect of changing the proportion of smokers in a population, thus facilitating strategic and robust planning14.

Here we present an ecological modelling study with the overarching aim of estimating the exposure–lag response of smoking prevalence on lung cancer incidence, while controlling for confounding variation attributable to country, age group, gender and population at risk. We chose smoking prevalence as our index of “exposure”, since this is the predominant diver of lung cancer incidence in a population15 Recent lung cancer incidence and population at risk estimates are matched by country, age group and gender to a complete 30-year exposure history of smoking prevalence data. We stipulated the following research questions:

  1. How does the exposure–response of smoking prevalence on lung cancer incidence vary by lag period?

  2. How does the lag–response of smoking prevalence on lung cancer incidence vary by smoking prevalence?

  3. How does the cumulative lag response of smoking prevalence on lung cancer incidence vary by smoking prevalence?

Material and methods

Annual age group (40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79 years) and gender (M/F) specific lung cancer incidence and corresponding populations at risk were obtained from the Cancer Incidence in Five Continents plus (CI5 plus) database for the period 2010 through 2012 inclusive from 105 cancer registries across 43 countries16 (Fig. 1). We excluded data for 19 cancer registries which were ethnicity grouped subsets of larger registries (for example, we retained USA-SEER, but discarded USA-SEER-White and USA-SEER-Black).

Figure 1.

Figure 1

Countries included in our analysis (shaded grey). The full list of countries include: Australia, Austria, Bahrain-Bahraini, Belarus, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech Republic, Denmark, Ecuador, Estonia, France, Germany, Iceland, India, Ireland, Israel, Italy, Japan, Korea, Kuwait, Lithuania, Malta, Netherlands, New Zealand, Norway, Philippines, Poland, Slovakia, Slovenia, Spain, Switzerland, Thailand, Turkey, Uganda, UK and the United States of America. Generated using R package “maptools” version ‘1.0.1’ (R version 4.0.2).

We obtained smoking prevalence estimates from the Institute for Health Metric and Evaluation (IHME) for the period 1980 through 2012 inclusive, matched by country, gender and age group17,18. The latter was matched retrospectively to properly characterise the smoking prevalence exposure history. For example, lung cancer incidence in the 75–79 age group in 2012 was matched with smoking prevalence for the 75–79 age group in 2012, the 70–74 age group in 2008 etc.

In order to model the temporal dependency between changes in smoking prevalence in a population and lung cancer incidence, we employed a distributed lag non-linear model (DLNM)19,20. Such models allow non-linearity in the bi-dimensional exposure–lag response surface and therefore offer a significant advantage to traditional approaches21,22. We define the statistical unit of analysis on demographic strata, i, (group of individuals, from country, C, in a given age group, A, of a given gender, G) at time t (outcome year = 2010, 2011, 2012).

Our statistical model took the form:

YitNegativebinomialμit,logμit=α+logPit+βSit,l+γCit+δAit+ηGit+λOit+νAitGit 1

where Yit is the observed lung cancer incidence, μit the expected (mean) lung cancer incidence, α the model intercept, and Pit the population at risk. Sit,l is a cross-basis matrix for smoking prevalence, with l representing the lag (= 0,1,2…30 years) and β a vector of coefficients. Cit,Ait and Oitare fixed effect categorical variables for country, age group, and outcome year respectively, with γ,δ and λ each representing the respective vectors of coefficients. AitGit represents an interaction term between age group and gender with ν its vector of coefficients. Git is a binary variable representing gender, set to 1 for male and 0 otherwise, with η its corresponding coefficient. The cross-basis matrix Sit,l was constructed using restricted cubic splines (i.e. natural splines) with 4 pre-specified degrees of freedom for both the lag and exposure bases. Spline functions were used as opposed to simple polynomial terms since the latter will not fit many functional forms23. Restricted cubic splines were chosen over cubic splines for two reasons: (1) the function is constrained to be linear in the tails (before the first knot and after the last knot) improving performance; and (2) only k − 1 parameters must be estimated (besides the intercept) as opposed to k + 3 parameters with the unrestricted cubic spline23.

The most recent year of outcome data (i.e. lung cancer incidence) in CI5 plus is 2012. The decision to include earlier outcome years must be weighed against the reduction in maximal lag period (this must remain constant when modelling several outcome years). We opted for a 30-year lag period15,24 which enabled us to include data from three lung cancer outcome years, namely 2010, 2011 and 2012. Accordingly, lung cancer outcomes in 2010, 2011 and 2012 utilised lagged smoking prevalence histories of 1980–2010, 1981–2011 and 1982–2012 respectively. We applied a constraint in the model described in Eq. (1) by excluding the intercept in the lag dimension of the cross-basis term. This had the effect of fixing the Incidence Rate Ratio (IRR, see below) to 1 at lag = 0 years, implying that changing the proportion of smokers in a population has no immediate effect on lung cancer incidence within the same year. The natural logarithm of Pit constitutes the model offset to account for varying populations at risk. Estimates of parameters was performed using full maximum likelihood. We pre-specified three additional competing models which were reduced forms of Eq. (1), those being: (1) omission of the interaction term between gender and age; (2) reduction from 4 to 3 degrees of freedom for each of the restricted cubic splines in the cross-basis term; and (3) both of the above. However, the full model (i.e. Eq. 1) outperformed these competing models as verified by Akaike’s Information Criterion (AIC). To check the assumptions of our selected model, we computed scaled (quantile) residuals using a simulation-based approach25.

The estimated coefficients and variance–covariance matrix of Sit,l were used to predict the exposure–lag response. We used the sandwich estimator to correct the variance–covariance matrix of Sit,l using registry as a cluster variable2628. Accordingly, standard errors were robust to autocorrelation and heteroskedasticity. Effects are presented as the incidence rate ratio (IRR) (± 95% confidence intervals) to quantify the direction and magnitude of the exposure–lag–response. The IRR represents the ratio of lung cancer incidence rate in the “exposed” group (i.e. specified increment in smoking prevalence compared to some reference level) to the lung cancer incidence rate in the ‘non-exposed” group (i.e. smoking prevalence at the reference level). Accordingly, the IRR represents the effect that changing the proportion of smokers in a population has on lung cancer incidence. Because we accounted for other covariates, the predicted changes in lung cancer incidence are “standardized” and represent the average effect, pooled over age groups, gender, country and outcome year. For analysis and interpretation, we set the reference level to 50% smoking prevalence, though corresponding figures with the reference level set at the maximum smoking prevalence value from the exposure history are provided in the supplementary material. We also computed cumulative incidence rate ratios (IRRcum) at each lag, by summing the logarithm of IRR’s from previous lags. These represent the incremental effects of IRR’s for a given smoking prevalence history. Since our study design incorporated multiple exposure events (i.e. smoking prevalence histories) IRR and IRRcum for the exposure–lag response are estimated from the “backward-perspective”19,20.

All statistical analyses was performed in R version 4.0.229 relying heavily on the packages dlnm, MASS and DHARMa19,25,30. Fully reproducible R code is included in the supplementary material.

Results

The number of lung cancer cases and corresponding populations at risk, aggregated across registries and countries, is shown in Table 1. Model checking plots of the simulated residuals indicated a good fit to the observed data with residuals close to the 1:1 line of observed vs. expected (supplementary information Fig 1).

Table 1.

Number of lung cancer cases and corresponding populations at risk by year, gender and age group.

Years Gender Age group (years) Number of cases Population at risk
2010 Female 40–44 1844 22,856,931
2010 Female 45–49 5245 23,960,807
2010 Female 50–54 10,221 23,072,194
2010 Female 55–59 14,246 20,691,616
2010 Female 60–64 20,680 18,415,911
2010 Female 65–69 24,933 14,027,181
2010 Female 70–74 25,709 11,412,962
2010 Female 75–79 25,272 9,774,883
2010 Male 40–44 1874 22,599,303
2010 Male 45–49 5879 23,513,387
2010 Male 50–54 13,273 22,401,557
2010 Male 55–59 21,862 19,638,456
2010 Male 60–64 31,335 17,208,726
2010 Male 65–69 37,182 12,590,896
2010 Male 70–74 38,012 9,572,416
2010 Male 75–79 35,099 7,372,029
2011 Female 40–44 1779 22,515,379
2011 Female 45–49 4888 23,205,727
2011 Female 50–54 10,140 22,878,792
2011 Female 55–59 14,662 20,711,581
2011 Female 60–64 20,963 18,732,935
2011 Female 65–69 25,533 14,106,947
2011 Female 70–74 25,973 11,342,181
2011 Female 75–79 24,426 9,590,696
2011 Male 40–44 1857 22,203,201
2011 Male 45–49 5298 22,795,845
2011 Male 50–54 12,433 22,235,507
2011 Male 55–59 21,238 19,662,798
2011 Male 60–64 30,814 17,480,755
2011 Male 65–69 36,380 12,728,774
2011 Male 70–74 37,431 9,580,269
2011 Male 75–79 33,621 7,314,162
2012 Female 40–44 1705 22,288,992
2012 Female 45–49 4665 22,633,652
2012 Female 50–54 10,155 22,775,001
2012 Female 55–59 15,496 20,969,853
2012 Female 60–64 20,874 18,565,286
2012 Female 65–69 27,149 14,989,704
2012 Female 70–74 26,907 11,532,883
2012 Female 75–79 24,943 9,558,073
2012 Male 40–44 1741 21,950,722
2012 Male 45–49 4822 22,243,431
2012 Male 50–54 11,989 22,149,777
2012 Male 55–59 21,126 19,897,569
2012 Male 60–64 30,103 17,277,257
2012 Male 65–69 37,420 13,561,101
2012 Male 70–74 37,526 9,787,986
2012 Male 75–79 33,359 7,344,897

Cases and population at risk counts are aggregated across registries and countries.

Across the bidimensional surface of all smoking prevalence and lag values, minimum IRR was 0.77 [95% CI 0.74, 0.83] occurring at smoking prevalence = 81% and lag = 16 years, whilst maximum IRR was 1.25 [95% CI 1.17, 1.34] occurring at smoking prevalence = 81% and lag = 6 years (Fig. 2). There was a clear interaction effect between increments in smoking prevalence and lag on the IRR, whereby the response to changes in smoking prevalence were dependant on the lag and vice versa.

Figure 2.

Figure 2

Bi-dimensional exposure–lag response surface showing joint effect of lag (years) and smoking prevalence (%) on predicted incidence rate ratio (IRR) of lung cancer. Effects are relative to the reference level of 50% smoking prevalence.

The lag response was wave-like, with the direction and magnitude varying according to the direction and magnitude of the increment in smoking prevalence compared to the reference level (i.e. 50% smoking prevalence) (Fig. 3). Positive increments in smoking prevalence produced a lag–response exhibiting an inverted U-shape between approximately 0 and 11 years lag, U-shaped between approximately 11 and 23 years lag, and largely flat between approximately 23 and 30 years lag. Lag–response curves for negative increments in smoking prevalence were approximate inversions of the lag response for positive increments in smoking prevalence. Accordingly, the lag response was U-shaped at recent lags, followed by an inverted U-shape at later lags.

Figure 3.

Figure 3

Estimated lag response of the incidence rate ratio (IRR) and 95% confidence intervals for specified increments in smoking prevalence (%). IRR > 1 indicates a positive association whilst IRR < 1 indicates a negative association. Increments in smoking prevalence are relative to the reference level of 50% smoking prevalence. For example, for the panel entitled smoking prevalence 60%, this implies a percentage increase of 20% smoking prevalence in the population ((60–50)/50 × 100).

The exposure–response curves varied according to the lag period (Fig. 4). For example, at lag = 5 years, the curve form showed an approximately exponential increase, at lag = 10 years approximately linear increase, and lag = 15 years approximately parabolic. At recent lags e.g. 5 and 10 years, positive and negative increments in smoking prevalence compared to the reference level clearly show an increased (IRR > 1) and decreased (IRR < 1) incidence of lung cancer respectively. Interestingly, the model predicts IRR < 1 for positive increments in smoking exposure at lags of 15 and 20 years.

Figure 4.

Figure 4

Estimated smoking exposure response of the incidence rate ratio (IRR) and 95% confidence intervals for specified lag periods (years). IRR is computed using the reference level of 50% smoking prevalence (i.e. the mean across all lags and countries). Accordingly, the IRR = 1 at smoking = 50% for all panels on the plot.

Minimum IRRcum was 0.07 [95% CI 0.05, 0.09] at smoking prevalence = 1% and lag = 17 years, whilst maximum IRRcum was 4.67 [95% CI 2.90, 7.50] at smoking prevalence = 81% and lag = 10 years. Increments above and below the reference level of 50% smoking prevalence was associated with an increased and decreased IRRcum respectively, with the magnitude of the effect varying across the lag period (Fig. 5). Accordingly (with the exception of high smoking prevalence), across the entire lag period, interval estimates for IRRcum were ≥ 1 and ≤ 1 for positive and negative increments in smoking prevalence respectively. The cumulative lag response was approximately bell-shaped for increments in smoking prevalence above the reference level, with the peak IRRcum occurring at approximately lag = 10 years. The magnitude of the effect increased with greater increases in smoking prevalence relative to the reference level.

Figure 5.

Figure 5

Estimated lag response of the cumulative incidence rate ratio (IRRcum) for specified increases in smoking prevalence (%). Increments in smoking prevalence are relative to the reference level of 50% smoking prevalence. For example, for the panel entitled smoking prevalence 60%, this implies a percentage increase of 20% smoking prevalence in the population ((60–50)/50 × 100)).

Discussion

In this contribution, we investigated the effect that changing the proportion of smokers in a population (i.e. smoking prevalence) has on standardized lung cancer incidence. This was achieved using a DLNM to quantify non-linear exposure–response dependencies and delayed effects20. We utilised data from 105 cancer registries across 43 countries and a complete smoking prevalence exposure history of 30 years. By incorporating data from a large number of countries over an extended time period, we were able to capture a wide range of smoking prevalence values, enabling us to fully capture the exposure–lag response.

The associations between lung cancer incidence and increments in smoking prevalence reflected in our effect plots adds to the current body of evidence that smoking prevalence is a major driver of lung cancer incidence in a population3134. Heloma et al.35 showed an approximately positive linear association between smoking prevalence at 20 years lag and current lung cancer incidence in a male Finnish population as compared to the clearly non-linear response reported herein (Fig. 4; lag = 20 years). Our results also imply that for a given change in smoking prevalence in a population, the lag period might be shorter than previously thought (e.g. 20 years8; 30 years15), though we emphasize that this is dependent on the initial smoking prevalence rate as well as the magnitude and direction of any changes.

For positive increments in smoking prevalence, one might expect the IRR in the lag response curves to increase above 1 (implying a positive association) to some peak, before exponentially declining to plateau at IRR = 1 towards the end of the lag period. It follows that the reverse would be expected for negative increments in smoking prevalence. Our results in part show this response, though the IRR < 1 (for positive increments) and IRR > 1 (for negative increments) in the later lags is somewhat unexpected. A potential explanation for this paradox is offered by the harvesting hypothesis. Depletion of the pool of susceptible individuals after a period of exposure renders the observed population healthier than a counterfactual population36. Such harvesting should not be interpreted as a true protective association at longer lags, but rather an artefact due to a change in the underlying population36 The decline in IRR below 1 at lag 15 and 20 years if smoking prevalence is increased above the reference level of 50% might then represent the harvesting effect described above, viewed from a different perspective.

The exposure–response and lag–response trends are reflected in the cumulative effects plots (Fig. 5). The increase in magnitude of the response with larger increments in smoking prevalence is consistent with the positive relationship between smoking prevalence and lung cancer incidence. For positive increments in smoking prevalence, the decline in IRRcum after the peak at approximately 10 years might be a direct consequence of the harvesting effect detailed above. For positive increments in smoking prevalence, the IRRcum interval estimates never fall below 1 (except at very high increments in smoking prevalence) for the entire lag period implying the high risk (IRR > 1) at earlier lags has compensated for any apparent protective association (IRR < 1) at later lags. Conversely, for negative increments in smoking prevalence, the interval estimate for IRRcum is less than 1 for the entire lag period, implying any apparent positive association at later lags (IRR > 1) has been compensated by negative associations (IRR < 1) at earlier lags.

Although our model included covariates (age group, gender, country, outcome year) to control for confounding variation, further analyses might consider additional known predictors of lung cancer such as ethnicity37 or socioeconomic status38. Furthermore, our model assumes that the exposure–lag response of smoking prevalence on lung cancer incidence is independent of our modelled covariates. This is a strong assumption; for example Chang et al.11 reported a significant age-by-pack-years interaction, whilst studies in Asia have reported a higher female to male ratio of the relative risk compared to non-Asian studies15,39,40. One way of relaxing such assumptions might be to adopt a two-stage design41. In the first stage, a series of covariate-specific DLNM’s are fitted, after which the cross-basis terms Sit,l are reduced to simpler sets of one-dimensional coefficients and covariances for the exposure- and lag–dimensions respectively. In the second stage, these are then pooled using meta-analysis.

We chose smoking prevalence as our smoking index since this is a strong predictor of lung cancer incidence in a population15. Although it is possible to include multiple cross-basis terms in DLNM’s, we decided against this to avoid the issue of multicollinearity, since our principle aim was to isolate the exposure–lag response of smoking prevalence on lung cancer incidence. Nevertheless, future studies might consider other indices of smoking history such as cigarette sales. Recent work has extended the DLNM framework through the use of penalized splines within generalized additive models (GAM)42, which provide built‐in model selection procedures and the possibility of accommodating assumptions on the shape of the lag structure through specific penalties43. It has been shown that this penalized extension to DLNM’s provides greater flexibility and improved inferential properties43 and so this approach might be considered in future works.

Using our model, the analyst can estimate IRRcum for given smoking prevalence scenarios (i.e. changes in the proportion of smokers in a population) over desired future time periods. IRRcum point estimates and confidence intervals are easily obtained from our model predictions (R code in supplementary material), by specifying a smoking prevalence reference level, the increment relative to the reference level, and the future time period. For example, reducing the percentage of smokers in a population from 50 to 40% (i.e. 20% reduction) for a period of 10 years hence is estimated to produce a 54% [95% CI 45%, 64%] reduction in the lung cancer incidence rate (IRRcum = 0.65 [95% CI 0.61, 0.69]). This can be easily demonstrated by use of interactive plotting software. We have used the R Shiny package44 to demonstrate the utility of our model for users to examine the effect that can be expected if the smoking prevalence is changed over a future time span of 30 years (https://abehzadnia.shinyapps.io/LungCa_Exposure_lag_response-Smith_et_al_2021/). One can also accommodate more complex scenarios where the smoking prevalence rate changes across time. The fact that the analyst need only input smoking prevalence to make these predictions makes our model particularly attractive since projections are widely available for many countries3.

It should be reminded that the smoking prevalence data we used herein are modelled estimates, and therefore subject to inherent uncertainties, discussed well elsewhere1. Our DLNM requires complete ordered data over the time series, and to our knowledge, no such global dataset of observed data exists. However, the smoking dataset used in this analysis is from a highly credible source which has undergone a rigorous validation process and was hence chosen because we believed it to be the most suitable for our study.

A final word of caution is that interpretation of time-varying IRR’s is certainly non-trivial and may not convey a sense of the true burden associated with changing smoking prevalence in populations. For example, if the baseline lung cancer incidence rate is very small, even a relatively large IRR might not lead to a big difference in cumulative lung cancer incidence between exposed and unexposed groups. Accordingly, computation of absolute risks in future work would be particularly useful for decision makers.

Conclusions

This was the first study to quantify the effect that changing smoking prevalence in a population has on lung cancer incidence. The exposure–response varied by lag period, whilst the lag–response varied according to the magnitude and direction of changes in smoking prevalence in the population. For the cumulative lag–response, increments above and below the reference smoking prevalence level was associated with an increased and decreased IRRcum respectively, with the magnitude of the effect varying across the lag period. By isolating the exposure–lag response, our model can be used to perform simple “what-if” analyses; that is, assessing changes in lung cancer incidence as a result of modifying the proportion of smokers in a population. We hope our work constitutes a preliminary step towards providing policy makers with meaningful indicators to inform national screening programme developments. To that end, we have implemented our model as an easy-to-use shiny app and provided an example of its use.

Supplementary Information

Supplementary Figures. (515.6KB, pdf)
Supplementary Data. (895KB, csv)
Supplementary Code. (10.1KB, r)

Author contributions

D.R.S., A.B. & M.L.G. designed the study. D.R.S., A.B., R.A.I. and M.N.S. wrote the main manuscript text. D.R.S. performed statistical analysis and generation of figures in the manuscript. A.B. implemeted the model as a shiny application.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-021-91644-y.

References

  • 1.Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. [DOI] [PubMed] [Google Scholar]
  • 2.Britton J. Progress with the global tobacco epidemic. Lancet. 2015;385:924–926. doi: 10.1016/S0140-6736(15)60498-6. [DOI] [PubMed] [Google Scholar]
  • 3.Bilano V, et al. Global trends and projections for tobacco use, 1990–2025: an analysis of smoking indicators from the WHO comprehensive information systems for tobacco control. Lancet. 2015;385:966–976. doi: 10.1016/S0140-6736(15)60264-1. [DOI] [PubMed] [Google Scholar]
  • 4.Brewer, J. & Potenza, M. Substance abuse and dependence. In Encyclopedia of Neuroscience, 591–597. 10.1016/B978-008045046-9.00534-9 (2009).
  • 5.World Health Organization. (World Health Organization, Geneva, 2003).
  • 6.Hoffman SJ, et al. Cigarette consumption estimates for 71 countries from 1970 to 2015:systemic collection of comparable data to facilitate quasi-experimental evaluations of national and global tobacco control interventions. BMJ. 2019;365:12231. doi: 10.1136/bmj.l2231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Reitsma MB, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the global burden of disease study 2015. Lancet. 2017;389:1885–1906. doi: 10.1016/S0140-6736(17)30819-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl. Lung Cancer Res. 2015;4:327–338. doi: 10.3978/j.issn.2218-6751.2015.08.04. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lubin JH, Caporaso NE. Cigarette smoking and lung cancer: modeling total exposure and intensity. Cancer Epidemiol. Biomark. Prev. 2006;15:517–523. doi: 10.1158/1055-9965.Epi-05-0863. [DOI] [PubMed] [Google Scholar]
  • 10.Remen T, Pintos J, Abrahamowicz M, Siemiatycki J. Risk of lung cancer in relation to various metrics of smoking history: a case-control study in Montreal. BMC Cancer. 2018;18:1275. doi: 10.1186/s12885-018-5144-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Chang ET, Lau EC, Moolgavkar SH. Smoking, air pollution, and lung cancer risk in the nurses' health study cohort: time-dependent confounding and effect modification. Crit. Rev. Toxicol. 2020;50:189–200. doi: 10.1080/10408444.2020.1727410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Matt GE, et al. Persistent tobacco smoke residue in multiunit housing: Legacy of permissive indoor smoking policies and challenges in the implementation of smoking bans. Prev. Med. Rep. 2020;18:101088. doi: 10.1016/j.pmedr.2020.101088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yu XQ, Luo Q, Hughes S, et al. Statistical projection methods for lung cancer incidence and mortality: a systematic review. BMJ Open. 2019;9:e028497. doi: 10.1136/bmjopen-2018-028497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lantz PM. Smoking on the rise among young adults: implications for research and policy. Tob. Control. 2003;12(Suppl 1):60–70. doi: 10.1136/tc.12.suppl_1.i60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Alberg AJ, Nonemaker J. Who is at high risk for lung cancer? Population-level and individual-level perspectives. Semin. Respir. Crit. Care Med. 2008;29:223–232. doi: 10.1055/s-2008-1076742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ferlay, J., Colombet, M. & Bray, F. Cancer Incidence in Five Continents, C15plus : IARC CancerBase No. 9. https://ci5.iarc.fr/CI5plus/Default.aspx (2018).
  • 17.Ng M, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA. 2014;311:183–192. doi: 10.1001/jama.2013.284692. [DOI] [PubMed] [Google Scholar]
  • 18.The Institute for Health Metrics and Evaluation (IHME) University of Washington. Global Health Data Exchange. http://ghdx.healthdata.org/sites/default/files/record-attached-files/IHME_GBD_2015_SMOKING_PREVALENCE_1980_2015_1.zip. (2020).
  • 19.Gasparrini A. Distributed lag linear and non-linear models in R: the package dlnm. J. Stat. Softw. 2011;43:1–20. doi: 10.18637/jss.v043.i08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Gasparrini A, Armstrong B, Kenward MG. Distributed lag non-linear models. Stat. Med. 2010;29:2224–2234. doi: 10.1002/sim.3940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Richardson DB. Latency models for analyses of protracted exposures. Epidemiology. 2009;20(3):395–399. doi: 10.1097/EDE.0b013e318194646d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Schwartz J. The distributed lag between air pollution and daily deaths. Epidemiology. 2000;11(3):320–326. doi: 10.1097/00001648-200005000-00016. [DOI] [PubMed] [Google Scholar]
  • 23.Harrell FE. Regression Modelling Strategies. Springer; 2015. [Google Scholar]
  • 24.Martín-Sánchez JC, Bilal U, Clèries R, Lidón-Moyano C, Fu M, González-de Paz L, Franco M, Fernandez E, Martínez-Sánchez JM. Modelling lung cancer mortality rates from smoking prevalence: fill in the gap. Cancer Epidemiol. 2017;49:19–23. doi: 10.1016/j.canep.2017.04.012. [DOI] [PubMed] [Google Scholar]
  • 25.DHARMa: residual diagnostics for hierarchical (multi-level/mixed) regression models (The Comprehensive R Archive Network, 2020).
  • 26.Zeileis A. Econometric computing with HC and HAC covariance matrix estimators. J. Stat. Softw. 2004;11:17. doi: 10.18637/jss.v011.i10. [DOI] [Google Scholar]
  • 27.Zeileis A. Object-oriented computation of sandwich estimators. J. Stat. Softw. 2006;16:16. doi: 10.18637/jss.v016.i09. [DOI] [Google Scholar]
  • 28.Susanne, B., Nathaniel, G. & Achim, Z. Various versatile variances: an object-oriented implementation of clustered covariances in R. (2017).
  • 29.R: A Language and Environment for Statistical Computing. v. R version 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria., 2013).
  • 30.MASS. (The Comprehensive RArchive Network, 2020).
  • 31.Ma Y, Li MD. Establishment of a strong link between smoking and cancer pathogenesis through DNA methylation analysis. Sci. Rep. 2017;7:1811. doi: 10.1038/s41598-017-01856-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Proctor RN. The history of the discovery of the cigarette-lung cancer link: evidentiary traditions, corporate denial, global toll. Tob. Control. 2012;21:87–91. doi: 10.1136/tobaccocontrol-2011-050338. [DOI] [PubMed] [Google Scholar]
  • 33.Yoshida K, et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature. 2020;578:266–272. doi: 10.1038/s41586-020-1961-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Hecht SS. Lung carcinogenesis by tobacco smoke. Int. J. Cancer. 2012;131:2724–2732. doi: 10.1002/ijc.27816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Heloma A, Nurminen M, Reijula K, Rantanen J. Smoking prevalence, smoking-related lung disease, and national tobacco control legislation. Chest. 2004;126:1825–1831. doi: 10.1378/chest.126.6.1825. [DOI] [PubMed] [Google Scholar]
  • 36.Gasparrini A, Leone M. Attributable risk from distributed lag models. BMC Med. Res. Methodol. 2014;14:55. doi: 10.1186/1471-2288-14-55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Pinsky PF. Racial and ethnic differences in lung cancer incidence: how much is explained by differences in smoking patterns? (United States) Cancer Causes Control. 2006;17:1017–1024. doi: 10.1007/s10552-006-0038-2. [DOI] [PubMed] [Google Scholar]
  • 38.Hovanec J, Siemiatycki J, Conway DI, Olsson A, Stücker I, Guida F, et al. Lung cancer and socioeconomic status in a pooled analysis of case-control studies. PLoS ONE. 2018;13(2):e0192999. doi: 10.1371/journal.pone.0192999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Powell HA, Iyen-Omofoman B, Hubbard RB, Baldwin DR, Tata LJ. The association between smoking quantity and lung cancer in men and women. Chest. 2013;143:123–129. doi: 10.1378/chest.12-1068. [DOI] [PubMed] [Google Scholar]
  • 40.O'Keeffe LM, et al. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open. 2018;8:e021611. doi: 10.1136/bmjopen-2018-021611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Gasparrini A, Armstrong B. Reducing and meta-analysing estimates from distributed lag non-linear models. BMC Med. Res. Methodol. 2013;13:1. doi: 10.1186/1471-2288-13-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Wood SN. Generalized Additive Models. 2. CRC Press; 2017. [Google Scholar]
  • 43.Gasparrini A, Scheipl F, Armstrong B, Kenward MG. A penalized framework for distributed lag non-linear models. Biometrics. 2017;73(3):938–948. doi: 10.1111/biom.12645. [DOI] [PubMed] [Google Scholar]
  • 44.Chang, W. et al. (2021). shiny: Web Application Framework for R. R package version 1.6.0. https://CRAN.R-project.org/package=shiny.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figures. (515.6KB, pdf)
Supplementary Data. (895KB, csv)
Supplementary Code. (10.1KB, r)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES